Kasumi-3 In Vitro Anti-Tumor Efficacy Assay

This assay is to provide Kasumi-3-based In Vitro Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

Kasumi-3

Human

The cell line was established from the blast cells of a myeloperoxidase-negative acute leukemia patient.
Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GMCSF) or stem cell factor induced the proliferation, characteristic of undifferentiated leukemia.

Acute Myeloblastic Leukemia; AML

Oncology

In Vitro Anti-Tumor Efficacy Assay

Kasumi-3-cell based In Vitro Anti-Tumor Efficacy Assay

Tumor-derived cell lines have been the mainstay for anti-cancer drug discovery, and the assessment of in vitro efficacy is a common method to evaluate the anti-cancer efficacy with various kinds of therapeutic candidates.

Oncology Efficacy Assays